论文部分内容阅读
近年来表观遗传学修饰在恶性肿瘤发生发展中的作用日益引起人们重视。白血病患者中存在着组蛋白修饰的异常,H3K9甲基化失平衡与白血病的发生发展相关。SUV39H1是第一个被发现的特异性H3K9甲基转移酶,催化H3K9甲基化从而参与异染色质形成及基因转录调控。通过纠正H3K9的甲基化异常,使高甲基化失活的抑癌基因再度表达,将有望为白血病的治疗提供新的靶点。本文就组蛋白H3K9甲基化如何影响基因转录调控、沉默基因表达及H3K9甲基化与白血病的关系进行了综述。
In recent years, the role of epigenetic modification in the development of malignant tumors has drawn increasing attention. There is abnormal histone modification in leukemia patients. The imbalance of H3K9 methylation is associated with the occurrence and development of leukemia. SUV39H1 is the first H3K9 methyltransferase to be found that catalyzes H3K9 methylation to participate in heterochromatin formation and gene transcription regulation. By correcting the methylation abnormality of H3K9 and re-expressing the tumor suppressor gene with high methylation inactivation, it is expected to provide a new target for the treatment of leukemia. This review summarizes how histone H3K9 methylation affects transcriptional regulation of genes, silencing gene expression, and the relationship between H3K9 methylation and leukemia.